PNC-27 research monograph — the chimeric p53-penetratin anticancer peptide
PNC-27 is one of the most mechanistically unusual compounds in research-vendor catalogues — and one of the most important to frame carefully. It is an experimental anticancer peptide that kills transformed cells not through the classical p53 tumour-suppressor transcription programme, but by punching selective pores in the cancer-cell membrane. It is a purely preclinical research molecule with no approved use and no established human safety data, and this monograph treats it accordingly: what it is, the membrane-HDM-2 mechanism that makes it selective, the (entirely laboratory) evidence base, and the heavy caveats a researcher must keep in view.
Chemical identity and structure.
PNC-27 is a 32-residue chimeric peptide. It joins the HDM-2-binding domain of the p53 protein (residues 12–26) to a cell-penetrating "leader" sequence — the penetratin peptide derived from the Antennapedia homeodomain. The p53 fragment supplies target recognition; the penetratin segment supplies membrane interaction.
Mechanism of action.
PNC-27's selectivity is the headline. Cancer cells frequently express HDM-2 (the human homologue of MDM2) in their plasma membrane; normal, untransformed cells generally do not. PNC-27 binds this membrane-bound HDM-2 in a p53-peptide-like conformation and induces the formation of transmembrane pores, leading to tumour-cell lysis and necrosis. Immuno-scanning electron microscopy has visualised ring-shaped, gold-labelled complexes in the pores, supporting a 1:1 PNC-27:HDM-2 pore model. The peptide has also been reported to disrupt mitochondrial membranes. Crucially, no pores form in PNC-27-treated normal fibroblasts, which lack membrane HDM-2 — this is the mechanistic basis for the compound's reported cancer selectivity. The killing is necrotic and membrane-mediated, not the transcription-dependent apoptosis usually associated with p53.
Research applications and the evidence base.
PNC-27 has been studied in vitro and in animal models across several cancers, including leukaemia and solid-tumour lines, with reported activity in cervical-cancer and other models. The entire evidence base is preclinical. There is no FDA approval, no completed human efficacy trial, and no established human safety profile. Any discussion of PNC-27 should foreground this: it is a research tool for studying membrane-HDM-2 biology and selective cytolysis, not a treatment.
Community protocol information.
PNC-27 is sold as lyophilized powder in vial sizes that vary widely (commonly cited from a few milligrams up to 30 mg), reconstituted with bacteriostatic or sterile water and kept refrigerated and protected from light. Where protocol figures are circulated, they are extrapolated from preclinical work (e.g. intravenous ranges of roughly 0.1–1 mg/kg delivered over weeks in animal studies) and its half-life is poorly documented. These figures are not human protocols, not recommendations, and not validated for safety — they are research-context summaries only, and PNC-27's anticancer, preclinical, no-human-data status makes that framing especially important.
Stack combinations researchers commonly use.
PNC-27 is not a recovery, metabolic, or performance compound, and there is little established combination literature for it. It is studied largely as a single agent in cytolysis and membrane-HDM-2 models; researchers occasionally examine it alongside other p53-pathway tools, but the combination evidence is minimal and should not be presented as a protocol.
Storage and handling.
Store lyophilized PNC-27 at −20 °C or colder (−80 °C is ideal for long-term), dry and dark; short-term refrigeration at 2–8 °C is acceptable for days to weeks. After reconstitution, refrigerate at 2–8 °C, protect from light, use within roughly 30 days, and avoid freeze–thaw.
Quality and COA considerations.
A meaningful COA should confirm identity by mass spectrometry against the 32-residue mass, report purity by HPLC (≥95–98% is a reasonable benchmark for a peptide of this length, where synthesis truncations are common), report residual TFA (a synthesis counter-ion), and — because the research uses involve membranes and cells — report endotoxin. Purity matters more than usual here: truncated synthesis by-products of a pore-forming peptide are an obvious confounder in any cytolysis assay.
Research-use note: This monograph is an educational summary of the published preclinical literature for PNC-27, a chimeric p53-penetratin peptide. PNC-27 is for laboratory and research use only. It has no FDA approval, no completed human efficacy trial, and no established human safety data; none of the figures above is a therapy, a dose recommendation, or a clinical protocol, and nothing here is medical advice.